HISTORY
In 1925, Merro Pharmaceuticals was founded in Dalian Manchurian Health Research Institute. In 1957, it was the first to develop erythromycin in China and become the earliest antibiotic production base in New China. In 1989, a joint venture with Pfizer Pharmaceuticals of the United States established China Pfizer Pharmaceutical Co., Ltd., the first large-scale joint venture in China. In 2000, the first batch passed the national GMP certification.
DEVELOPMENT
In the past 100 years, Merro has never stopped the pace of development. In 2005, it obtained TGA international certification, and in the same year, it exported to New Zealand, which is the first batch of preparation export enterprises in China. In 2014, the solid preparation workshop passed the US FDA certification. In 2015, acquired Polygen Pharmaceutical Factory in the US In 2017, sustained-release preparations were exported to Australia, and multiple ANDA products were approved in the US.
PRESENT
Based on more than 200 products, Merro focuses on the development of slow-release preparations and biological agents, and promotes the extensive cooperation of products and technologies in the international pharmaceutical market, and continuously enhances the company's innovation capabilities to build a factory that meets GMP standards in advanced countries such as Europe and the United States. As the center, we will vigorously develop international and domestic markets and build an international pharmaceutical company that uses technology, service excellence and innovation.
THE MARKET
Merro's products serve 30 provinces and cities through a comprehensive sales network, and enter more than 10,000 medical institutions in China.
Realized terminal sales in more than 50,000 pharmacies, and has achieved strategic partnership with the top 20 KA customers in the country, and deep cooperation in 8 major pharmaceutical e-commerce platforms.
Through three major channels, comprehensive coverage of prescription drugs, OTC products, health care products, toiletries and killing products
Provide health solutions for consumers of all ages across the country
Merro's products serve 30 provinces and cities through a comprehensive sales network, and enter more than 10,000 medical institutions in China. Realized terminal sales in more than 50,000 pharmacies, and has achieved strategic partnership with the top 20 KA customers in the country, and deep cooperation in 8 major pharmaceutical e-commerce platforms. Through three major channels, comprehensive coverage of prescription drugs, OTC products, health care products, toiletries and killing products Provide health solutions for consumers of all ages across the country
ASPIRATION
In the future, Merro Pharmaceuticals will continue to promote pharmaceutical innovation, drive pharmaceutical manufacturing business and marketing upgrades to create a healthier and better future for mankind. Merro only exists for health.
0411-84795668
No. 9, Yingsheng Road, Yingchengzi Industrial Park, Ganjingzi District, Dalian
Copyright © 2000-2019 Merro Pharmaceutical Co.,Ltd
LN-ICP-11010262
辽公网安备 21021102000688号